FIELD: chemistry.
SUBSTANCE: peptides and peptide derivatives have general formula Sub1-X1NX2X3PVYIPX4X5RPPHP-Sub2, where Sub1, X1, X2, X3, X5, Sub2 are given in the claim. The disclosed peptides or peptide derivatives have at least one of the following advantages compared to natural apidecine peptides: (i) longer half-life in mammal serum owing to higher protease stability, (ii) high antimicrobial activity with respect to one or more bacterial strains, particularly human pathogens or fungi, or other microbial infections, (iii) demonstrate a wide range of antimicrobial activity, (iv) cause slower development of resistance in microorganisms and (v) are not toxic for human cells, including erythrocytes.
EFFECT: improved properties of peptides.
21 cl, 8 dwg, 7 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIMICROBIAL PEPTIDES | 2013 |
|
RU2660351C2 |
ANTIBACTERIAL PEPTIDES | 2007 |
|
RU2468033C2 |
PEPTIDES, DETACHED FROM HUMAN LACTOFERRIN, AND USE THEREOF | 2012 |
|
RU2593757C2 |
PEPTIDE ANTAGONISTS OF PEPTIDE HORMONES FROM THE CALCITONIN GROUP (CALCITONIN GENE-RELATED PEPTIDES (CGRP)) AND THEIR APPLICATION | 2013 |
|
RU2624016C2 |
NOVEL SYNTHETIC PEPTIDES AND USE THEREOF | 2012 |
|
RU2596393C2 |
VACCINE COMPOSITION | 2001 |
|
RU2328305C2 |
ANTI-AGING AND WOUND-HEALING COMPOSITIONS | 2002 |
|
RU2318873C2 |
APOPTOSIS INHIBITORS AND USE THEREOF | 2011 |
|
RU2582247C2 |
AGONISTS OF APOLIPOPROTEIN A-1 AND THEIR APPLICATION FOR TREATMENT OF DYSLIPIDEMIA-ASSOCIATED DISEASES | 1998 |
|
RU2219941C2 |
INSULIN-INCRETIN CONJUGATES | 2014 |
|
RU2678134C2 |
Authors
Dates
2013-01-20—Published
2008-07-21—Filed